Ranjit S. Bindra

Biomarker-Targeted O6-Guanine Alkylation Potentiates ATR Inhibitor Response in De Novo and Relapsed/Refractory AML

This study identifies MGMT silencing as a therapeutic target in AML and shows that combining O6-fluoroethylating agents with ATR inhibitors improves treatment outcomes.

Leveraging Homologous Recombination Deficiency via the Repositioned Prodrug CB1954

This paper identifies CB1954 as a selective therapy for BRCA2-deficient cancers by showing its activity in HRD cells and mechanism of action.

On-target toxicity limits the efficacy of CDK11 inhibition against cancers with 1p36 deletions

This study shows CDK11 is critical for cancer cell survival and identifies 1p36 deletions as a biomarker for CDK11 inhibitor sensitivity, but on-target toxicity limits therapeutic efficacy.